(Q41704948)

7 October 2017

1 reference

title

On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy (English)

1 reference

7 October 2017

author

Øyvind Sverre Bruland

series ordinal

1

object named as

Bruland OS

1 reference

7 October 2017

Pihl A

2

1 reference

7 October 2017

language of work or name

1 reference

1 October 1997

1 reference

European Journal of Cancer

7 October 2017

published in

1 reference

7 October 2017

volume

33

1 reference

7 October 2017

issue

11

1 reference

7 October 2017

page(s)

1725-1731

1 reference

Osteosarcoma of bone and its important recognizable varieties

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Chemotherapy for osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Population based survival rates for childhood cancer in Britain, 1980-91.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Osteogenic sarcoma with clinically detectable metastasis at initial presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

The therapy of osteogenic sarcoma: Current status and thoughts for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

The prognosis in osteosarcoma: Norwegian National Data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Results of multiple pulmonary resections for metastatic osteogenic sarcoma after two decades

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Pulmonary metastasectomy in patients with osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

The contribution of salvage surgery to the management of childhood osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Doxorubicin in disseminated osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Prognostic factors in osteosarcoma: a critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Changing metastatic patterns of osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Methotrexate pharmacokinetics and prognosis in osteosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Tumor size and prognosis in aggressively treated osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Immunoscintigraphy of bone sarcomas--results in 5 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900252-9

7 January 2021

10.1016/S0959-8049(97)00252-9

Identifiers

DOI

1 reference

7 October 2017

1 reference